SCHEMBL4028522

SCHEMBL4028522

Cc1cccc([C@H]2[CH]CN(Cc3ccccc3)C[C@@H]2C(=O)c2ccccc2)c1C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.46
SCN4A P35499 2/20 0.40
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
LMNA P02545 2/20 0.39
MAPK1 P28482 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
EP300 Q09472 1/20 0.38
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024600 0.87 L3MBTL1 (0.34) RORCALDH1A1MEN1MAPK1KMT2A
SCHEMBL4026679 0.87 L3MBTL1 (0.34) RORCALDH1A1MEN1MAPK1KMT2A
SCHEMBL4027448 0.87 KDM2B (0.37) RORCALDH1A1MEN1LMNAKMT2A
SCHEMBL4026766 0.86 KIF11 (0.41) RORCALDH1A1MEN1LMNAKMT2A
SCHEMBL4021821 0.86 KIF11 (0.41) RORCALDH1A1MEN1LMNAKMT2A
SCHEMBL4027189 0.85 KCNH2 (0.35) RORCALDH1A1LMNAKMT2ATSHR
SCHEMBL4020571 0.85 KCNH2 (0.35) RORCALDH1A1LMNAKMT2ATSHR
SCHEMBL4026061 0.84 KIF11 (0.43) RORCALDH1A1MEN1LMNAKMT2A
SCHEMBL4025183 0.84 KIF11 (0.37) RORCALDH1A1
SCHEMBL4028852 0.84 KCNH2 (0.37) RORCALDH1A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 RORC 183/4885SCN4A 4754/4885ALDH1A1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.